Stockreport

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress...

Tonix Pharmaceuticals Holding Corp.  (TNXP) 
Last tonix pharmaceuticals holding corp. earnings: 3/24 05:15 pm Check Earnings Report
US:NASDAQ Investor Relations: tonixpharma.com
PDF TNX-4800 is a long-acting anti-Borrelia burgdorferi OspA human monoclonal antibody in development as a single-dose Lyme prophylactic Phase 1 study of TNX-4800 demonstrat [Read more]